Results 11 to 20 of about 9,527 (221)
Impact of urate-lowering therapy on quality of life indicators in patients with gout
Современная ревматология, 2021 Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina +2 more
doaj +1 more source
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
Antioxidants, 2023 Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS).
Yoshiki Higa +21 more
doaj +1 more source
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis [PDF]
The Korean Journal of Internal Medicine, 2020 Background/Aims The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients.
Sang-Hyon Kim +3 more
doaj +1 more source
PLoS ONE, 2022 Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable.
Seokwoo Park +4 more
doaj +3 more sources
Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
Pharmaceuticals, 2018 The paper addresses the safety of febuxostat and summarizes reports on side effects and interactions of febuxostat published by the cut-off date (last day of literature search) of 20 March 2018.
Andreas Jordan, Ursula Gresser
doaj +1 more source
, 2008 INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES:We conducted a systematic review and aimed to answer the following clinical questions: What are the
Underwood, Martin
core +3 more sources
Febuxostat: a new drug for an old disease. Do we really need it?
Italian Journal of Medicine, 2013 BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj +1 more source
The role of urate and xanthine oxidase in vascular oxidative stress:Future directions [PDF]
, 2009 Vascular oxidative stress has been shown to be a potent factor in the pathophysiology of endothelial dysfunction. Despite current optimal evidence-based therapy, mortality from various cardiovascular disorders remains high.
George, Jacob, Struthers, Allan
core +5 more sources
The current treatment strategy for gouty arthritis
Современная ревматология, 2018 Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova +2 more
doaj +1 more source
Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity [PDF]
, 2014 Aims Obesity is a risk factor for diabetes and cardiovascular diseases, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue (AT) dysfunction that promotes bioactive mediator ...
Baust, Jeff +14 more
core +1 more source